United Kingdom· GB-APID-22133211000001103
Isradipine 2.5mg tablets
A isradipine product containing isradipine, registered in United Kingdom by Sandoz Ltd. The same ATC class is registered in 5 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Isradipine is registered in 5 of 19 countries.
Countries holding a registration under ATC C08CA03 (isradipine), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 4 of them publish a price we can compare per daily dose
Isradipine · ATC C08CA03
5 / 19 countries
- Belgiumprice
- Finlandprice
- Franceprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of isradipine costs, country by country.
Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Isradipine · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- US United States$1.99 (acquisition cost)
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Isradipine
- Manufacturer
- Sandoz Ltd
- Country
- United Kingdom (GB)
- ATC code
- C08CA03
- ATC class
- Isradipine
- Defined daily dose
- 5 mg, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5050650109016
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
283 interactions on record for isradipine.
Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Isradipine · interactions on record
283 records
- 8 severe
- 171 moderate
- 2 minor
- 55 info
Most severe, free to view
- DolasetronA04AA04severe
- CeritinibL01ED02severe
- CeritinibL01XE28severe
- MitotaneL01XX23severe
47 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Isradipine in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandLomirNovartis Finland Oy
- United StatesIsradipineAvKARE
- BelgiumLomir 2.5 mgSankyo Pharma Belgium
- FranceICAZ LP 2,5 mg, gélule à libération prolongéeFARMACEUTICO SIT
- ItalyCLIVOTEN*14 cps 5 mg rilascio prolungatoITALFARMACO SpA
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- France · Icaz Lp
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f8d4b80c-a833-4a04-82b5-5e4a91d94a4c GET /v1/drugs/f8d4b80c-a833-4a04-82b5-5e4a91d94a4c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "22133211000001103",
"desc": "Isradipine 2.5mg tablets (Sandoz Ltd)",
"form": "Oral tablet",
"vpid": "42212711000001106",
"source": "dmd",
"vtm_id": "776431008",
"strength": "2.5 mg",
"substance": "Isradipine",
"ingredient": "Isradipine",
"supplier_code": "2074301000001102"
}See everything about isradipine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.